Snapshot · The Peter Attia Drive
The Gila monster eats only 3 or 4 meals per year yet maintains remarkably stable blood glucose levels throughout prolonged fasting, which drew John Eng's scientific attention.
Where this was said
At 47:38 · chapter starts 47:30
In the late 1980s, clinical endocrinologist John Eng was seeing veterans with diabetes at the Bronx VA Medical Center and moonlighting in Rosalind Yalow's lab, which had developed uniquely sensitive peptide hormone assays using radioimmunoassay technology. Eng had read that Gila monster bites caused dramatic pancreatic inflammation in bitten animals, and he was struck by an additional fact: the Gila monster eats only 3 or 4 meals a year yet maintains stable blood glucose throughout long fasts — suggesting its pancreatic biology was doing something unusual. He ordered dried Gila monster venom and ran it through Yalow's assays. [1] — Peter Attia "Exendin-4 has 53% similarity to human GLP-1: Exendin-4, a peptide in Gila monster venom discovered by John Eng, showed 53% amino acid seque…" 48:58 Working with colleague Jean-Pierre Rothman, he systematically separated the peptide components, identified two peptides, and named the new one Exendin-4. When he sequenced it, the result was remarkable: 53% amino acid similarity to human GLP-1, the gut hormone that stimulates insulin secretion after meals. More importantly, while native GLP-1 has a half-life of only about 2 minutes — degraded almost instantly by the enzyme DPP-4 — Exendin-4 is resistant to DPP-4 and has a half-life measured in hours. Eng had discovered a long-acting GLP-1 receptor agonist hiding in lizard saliva. [2] — Peter Attia "Native GLP-1 half-life: ~2 minutes: Native human GLP-1 has a bloodstream half-life of only about 2 minutes due to rapid degradation by the …" 49:50 The VA declined to patent the discovery; Eng patented it himself and licensed it, eventually to Eli Lilly and Amylin. In 2005, the FDA approved synthetic Exendin-4 as Byetta (exenatide), the first GLP-1 receptor agonist. Subsequent drugs — liraglutide, semaglutide, tirzepatide — built on the biology, reducing immunogenicity and extending duration. The class is now reshaping the treatment of type 2 diabetes, obesity, and cardiovascular disease, with ongoing trials in heart failure, kidney disease, sleep apnea, addiction, and Alzheimer's disease.
Exendin-4, a peptide in Gila monster venom discovered by John Eng, showed 53% amino acid sequence similarity to human GLP-1, explaining its potent pancreatic effects.
Native human GLP-1 has a bloodstream half-life of only about 2 minutes due to rapid degradation by the DPP-4 enzyme, making it useless as a standalone drug.
Dan Gilbert's research found that the psychological immune system — the brain's ability to justify and find satisfaction in choices — activates most powerfully when a decision is perceived as irreversible.
Barry Schwartz's research found that maximizers — people who try to optimize every decision — tend to achieve objectively better outcomes but report lower happiness than satisficers who choose 'good enough.'
Research consistently shows that while people may initially regret poor decisions, in the long run they regret the decisions they didn't make — inaction — far more than the ones they took.
A study showed that men in committed relationships who briefly viewed 10 attractive women's faces reported a measurable decrease in relationship satisfaction immediately afterward, illustrating evolutionary mismatch with modern media.
Harvard psychologist Dan Gilbert, who previously didn't believe in marriage, immediately proposed to his long-term girlfriend after his own research showed that constraints increase satisfaction with choices.
Animals first sensed light 540 million years ago, triggering an evolutionary acceleration known as the Cambrian explosion within 10 million years.
It is estimated that half of all cortical activity in the human brain is involved in visual function, underscoring vision's central role in intelligence.
Cognitive neuroscience literature shows that by age 6, humans can recognize tens of thousands of different object categories — far more data than early AI systems were trained on.
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.